Oxygen Biotherapeutics Inc Share Price Nasdaq
Equities
US69207P3082
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.42M 536M |
---|---|---|---|---|---|
Net income 2024 * | -19M -1.59B | Net income 2025 * | -18M -1.5B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.4
x | P/E ratio 2025 * |
-0.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14/21/14 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/21/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04/14/04 |
June Almenoff
BRD | Director/Board Member | 67 | 25/21/25 |
Declan Doogan
BRD | Director/Board Member | 72 | 25/21/25 |
1st Jan change | Capi. | |
---|---|---|
+46.29% | 56.61B | |
-7.53% | 39.62B | |
+36.02% | 39.25B | |
-9.38% | 28.28B | |
+11.89% | 26.44B | |
-16.83% | 20.12B | |
+30.42% | 12.51B | |
+28.57% | 12.48B | |
-0.47% | 12.2B |